Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy

Blood

Volumn 121, Issue 2, 2013, Pages 278-285

  Gerrard, Mary ^a   Waxman, Ian M ^b   Sposto, Richard ^c   Auperin, Anne ^d   Perkins, Sherrie L ^e   Goldman, Stanton ^f   Harrison, Lauren ^g   Pinkerton, Ross ^h   McCarthy, Keith ⁱ   Raphael, Martine ^j   Patte, Catherine ^d   Cairo, Mitchell S ^g  

^a SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^f Medical City Children's Hospital   (United States)

^g NEW YORK MEDICAL COLLEGE   (United States)

^h UNIVERSITY OF QUEENSLAND   (Australia)

ⁱ GLOUCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

^j BICÊTRE HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHILD; CHILDHOOD; CLINICAL ARTICLE; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; HUMAN; LARGE CELL LYMPHOMA; MALE; MEDIASTINAL LARGE B CELL LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT RESPONSE;

EID: 84872324623     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-04-422709     Document Type: Article

References (40)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. WHO Classification of Tumours. Vol 3. Lyon, France: International Agency for Research on Cancer; 2001.
2. Swerdlow S, Campo E, Harris NL, eds; International Agency for Research on Cancer. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. Geneva, Switzerland: World Health Organization; 2008:1-439.
3. Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. Semin Oncol. 1980;7(3):332-339. (Pubitemid 11228642)
4. Lones MA, Perkins SL, Sposto R, et al. Large-cell lymphoma arising in the mediastinum in children and adolescents is associated with an excellent outcome: a Children's Cancer Group report. J Clin Oncol. 2000;18(22):3845-3853.
5. Seidemann K, Tiemann M, Lauterbach I, et al. Primary mediastinal large B-cell lymphoma with sclerosis in pediatric and adolescent patients: treatment and results from three therapeutic studies of the Berlin-Frankfurt-Munster Group. J Clin Oncol. 2003;21(9):1782-1789. (Pubitemid 46638592)
6. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198(6):851-862. (Pubitemid 37152922)
7. Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med. 2006; 354(23):2431-2442. (Pubitemid 43855046)
8. Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood. 2005;106(4):1164-1174. (Pubitemid 41129574)
9. Steidl C, Gascoyne RD. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood. 2011;118(10):2659-2669.
10. Cairo MS, Gerrard M, Sposto R, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2007;109(7):2736-2743. (Pubitemid 46482065)
11. Gerrard M, Cairo MS, Weston C, et al. Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study. Br J Haematol. 2008;141(6):840-847. (Pubitemid 351724873)
12. Patte C, Auperin A, Gerrard M, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007;109(7):2773-2780. (Pubitemid 46482070)
13. Harris N, Jaffe E, Stein H, et al.Arevised European- American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84(5):1361-1392. (Pubitemid 24273002)
14. Lones MA, Auperin A, Raphael M, et al. Mature B-cell lymphoma/leukemia in children and adolescents: intergroup pathologist consensus with the revised European-American Lymphoma Classification. Ann Oncol. 2000;11(1):47-51. (Pubitemid 30084578)
15. Miles RR, Raphael M, McCarthy K, et al. Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c-Myc protein expression, and a high incidence of germinal center subtype: Report of the French-American- British (FAB) International Study Group. Pediatr Blood Cancer. 2008;51(3):369-374.
16. Burkhardt B, Zimmermann M, Oschlies I, et al. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol. 2005;131(1):39-49. (Pubitemid 43899706)
17. Oschlies I, Burkhardt B, Salaverria I, et al. Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children. Haematologica. 2011;96(2):262-268.
18. Rodríguez J, Gutierrez A, Piris M. Primary mediastinal B-cell lymphoma: treatment and therapeutic targets. Leuk Lymphoma. 2008;49(6):1050- 1061.
19. Savage KJ. Rare B-cell lymphomas: primary mediastinal, intravascular, and primary effusion lymphoma. Cancer Treat Res. 2008;142:243- 264.
20. Todeschini G, Secchi S, Morra E, et al. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer. 2004;90(2):372-376. (Pubitemid 38250631)
21. Cairoli R, Grillo G, Tedeschi A, et al. Efficacy of an early intensification treatment integrating chemotherapy, autologous stem cell transplantation and radiotherapy for poor risk primary mediastinal large B cell lymphoma with sclerosis. Bone Marrow Transplant. 2002;29(6):473-477. (Pubitemid 34428714)
22. Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003;102(12):3871-3879. (Pubitemid 37486965)
23. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-Bcell lymphoma. N Engl J Med. 2002;346(4):235- 242.
24. Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2- associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood. 2003;101(11):4279-4284. (Pubitemid 36857789)
25. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7(5): 379-391.
26. Wilson WH, Dunleavy K, Pittaluga S, et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol. 2008;26(16): 2717-2724.
27. Dunleavy K, Pittaluga S, Shovlin M, et al. Untreated primary mediastinal B-cell (PMBL) and mediastinal grey zone (MGZL) lypmphomas: comparison of biological features and clinical outcome following DA-EPOCH-R without radiation [abstract]. Ann Oncol. 2011;22(Suppl 4):150.
28. Rieger M, Osterborg A, Pettengell R, et al. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol. 2011;22(3):664-670.
29. Cairo MS, Lynch JC, Harrison L, et al. Safety, kinetics, and outcome following rituximab (R) in combination with FAB chemotherapy in children and adolescents (C-A) with stage III/IV (Group B) and BM-/CNS- (Group C) mature B-NHL: A Children's Oncology Group report [abstract]. J Clin Oncol. 2010;28:9536.
30. Miles RR, Waxman I, van de Ven C, et al. Bortezomib (BTZ) IKK inhibitor ML120B and combination therpay induce apoptosis, inhibit NK-kB activation, and decrease specific proteins in primary mediastinal B-cell lymphoma (PMBL) [abstract]. Ann Oncol. 2011;22(Suppl 4):146.
31. Ritz O, Guiter C, Castellano F, et al. Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma. Blood. 2009;114(6):1236-1242.
32. Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116(17):3268-3277.
33. Möller P, Lammler B, Herrmann B, Otto HF, Moldenhauer G, Momburg F. The primary mediastinal clear cell lymphoma of B-cell type has variable defects in MHC antigen expression. Immunology. 1986;59(3):411-417.
34. Roberts RA, Wright G, Rosenwald AR, et al. Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival. Blood. 2006;108(1):311-318. (Pubitemid 43990644)
35. Steidl C, Shah SP, Woolcock BW, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature. 2011; 471(7338):377-381.
36. Cairo MS, Sposto R, Gerrard M, et al. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (-/- 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB LMB 96 study. J Clin Oncol. 2012;30(4):387-393.
37. Copie-Bergman C, Gaulard P, Maouche-Chretien L, et al. The MALgene is expressed in primary mediastinal large B-cell lymphoma. Blood. 1999;94(10): 3567-3575. (Pubitemid 29536153)
38. Copie-Bergman C, Plonquet A, Alonso MA, et al. MAL expression in lymphoid cells: further evidence for MAL as a distinct molecular marker of primary mediastinal large B-cell lymphomas. Mod Pathol. 2002;15(11):1172-1180. (Pubitemid 35435135)
39. Guiter C, Dusanter-Fourt I, Copie-Bergman C, et al. Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. Blood. 2004; 104(2):543-549. (Pubitemid 38900039)
40. Hochberg J, Waxman IM, Kelly KM, Morris E, Cairo MS. Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science. Br J Haematol. 2009;144(1):24-40.